The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...

Blau Farmacêutica, a Brazilian pharmaceutical company listed on Brazilian Stock Market (B3) and a regional leader in hospital pharmaceuticals with a strong presence across Latin America, announces an ...

India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved a wide range of recombinant DNA (r-DNA)-origin drugs and biologics for manufacture ...

China's drug regulator has granted conditional approval to Huahui Health's Libevitug injection for the treatment of the chronic hepatitis D virus infection in adults, the company said on Friday.

By CH Unnikrsihnan Drug maker and researcher Glenmark Pharmaceuticals Ltd's new biological drug candidate Bi-Specific ...

However, I see one "dark spot" in this acquisition. Merus's operating loss was $110.4 million in Q2, up 82.4% year-over-year, which will ultimately slow Genmab's EPS growth until at least 2028.

As of 22 January, 19 of the 23 patients who have received treatment are still alive, with the longest evaluable survival ...

More than 140 U.S. medical organizations are advocating for the passage of a bill that would increase NIH funding for fiscal ...

News, features, and commentary about cancer-related issues ...

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...

Metastatic urothelial carcinoma has a poor prognosis: ~50% of muscle-invasive bladder cancer progresses to metastasis, and ...